{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-063151","form_type":"8-K","ticker":"BZYR","cik":"0000724445","company_name":"BURZYNSKI RESEARCH INSTITUTE INC","filed_at":"2023-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.074913+00:00","generated_at":"2026-06-14T18:47:41.587008+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BZYR licenses antineoplaston patents from CEO; research funding secured through Feb 2024","bullets":["License from Dr. Burzynski for exclusive rights to four US patents and pending applications for antineoplastons in US/Canada.","Research Funding Agreement: Dr. Burzynski funds all basic research and FDA-related trial costs; term to Feb 2024, auto-renewable.","Amended Royalty and Research Funding Agreements limited to US/Canada scope.","License can terminate if Burzynski removed as officer/director or if another party equals his voting power."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-063151","json":"https://secwatch.observer/filing/0001104659-23-063151.json","markdown":"https://secwatch.observer/filing/0001104659-23-063151.md","text":"https://secwatch.observer/filing/0001104659-23-063151.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/724445/000110465923063151/0001104659-23-063151-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/724445/000110465923063151/tm2316366d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T18:47:41.587008+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}